Thesan Pharmaceuticals is a biotechnology company based in Carlsbad, CA, led by CEO J. Gordon Foulkes, Ph.D. The company focuses on the development and commercialization of novel therapeutics for dermatological conditions, including acne and atopic dermatitis. Thesan closed a $49m Series B financing to support its programs. It intends to use the funds to develop new candidate drugs in the dermatology space. As part of the financing, new board members from investor firms will join to support the company’s development plans. The company’s current financial update reflects the completed Series B round announced in February 2014. Thesan Pharmaceuticals is a San Clemente, CA-based biotechnology company developing and commercializing novel drugs for dermatological conditions. Its lead candidate is a topically-applied new chemical entity expected to enter the clinic in 2013. The company intends to use the Series A proceeds to develop novel approaches for the treatment of dermatological disorders. Thesan’s first products were licensed from the University of California, Irvine and were developed in the laboratory of Professor Daniele Piomelli. The company is led by Executive Chairman and CEO Gordon Foulkes. In conjunction with the financing, Peter Bisgaard and Tiba Aynechi from Novo, Giovanni Ferrara and Henry Skinner from Novartis, and Dr. Howard Welgus (former VP R&D for Dermatology/Inflammation at Pfizer) joined the company’s board.

Total raised

$65M

Funding rounds

2

Latest round

Series B

Latest activity

Feb 2014